Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Comparison between intensified neoadjuvant treatment and standard preoperative chemoradiation for rectal cancer.

Musio D, Raffetto N, Dionisi F, Iannacone E, Dipalma B, Caparrotti F, Meaglia I, Caiazzo R, Bangrazi C, Banelli E.

Tumori. 2010 Jan-Feb;96(1):11-6.

2.

Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.

Cancer and Leukemia Group B 89901, Ryan DP, Niedzwiecki D, Hollis D, Mediema BE, Wadler S, Tepper JE, Goldberg RM, Mayer RJ.

J Clin Oncol. 2006 Jun 1;24(16):2557-62. Epub 2006 Apr 24.

PMID:
16636336
3.

Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy.

Valentini V, Coco C, Minsky BD, Gambacorta MA, Cosimelli M, Bellavita R, Morganti AG, La Torre G, Trodella L, Genovesi D, Portaluri M, Maurizi-Enrici R, Barbera F, Maranzano E, Lupattelli M.

Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):403-12. Epub 2007 Oct 4.

PMID:
17919844
4.

Oxaliplatin with raltitrexed and preoperative radiotherapy in T3-T4 extraperitoneal rectal cancer. A dose finding study.

Lupattelli M, Bellavita R, Natalini G, Giovenali P, Sidoni A, Castagnoli P, Corgna E, Draghini L, Trippolini R, Aristei C.

Tumori. 2006 Nov-Dec;92(6):474-80.

PMID:
17260486
5.

Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies.

Valentini V, Coco C, Cellini N, Picciocchi A, Fares MC, Rosetto ME, Mantini G, Morganti AG, Barbaro B, Cogliandolo S, Nuzzo G, Tedesco M, Ambesi-Impiombato F, Cosimelli M, Rotman M.

Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):371-83.

PMID:
11567811
6.

Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.

Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M.

Dis Colon Rectum. 2004 Nov;47(11):1798-807.

PMID:
15622571
7.

Addition of weekly oxaliplatin to standard preoperative chemoradiation for locally advanced rectal cancer.

Aschele C, Lonardi S.

J Clin Oncol. 2007 Feb 10;25(5):602-3; author reply 603. No abstract available.

PMID:
17290071
8.

The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer.

Crane CH, Skibber JM, Birnbaum EH, Feig BW, Singh AK, Delclos ME, Lin EH, Fleshman JW, Thames HD, Kodner IJ, Lockett MA, Picus J, Phan T, Chandra A, Janjan NA, Read TE, Myerson RJ.

Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):84-9.

PMID:
12909219
9.

Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation.

Valentini V, Coco C, Cellini N, Picciocchi A, Rosetto ME, Mantini G, Marmiroli L, Barbaro B, Cogliandolo S, Nuzzo G, Tedesco M, Ambesi-Impiombato F, Cosimelli M, Rotman M.

Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1175-84.

PMID:
10613310
10.

Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation.

Valentini V, Coco C, Cellini N, Picciocchi A, Genovesi D, Mantini G, Barbaro B, Cogliandolo S, Mattana C, Ambesi-Impiombato F, Tedesco M, Cosimelli M.

Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1067-75.

PMID:
9539561
11.

Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.

Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, Cellini F, Barbaro B, Cogliandolo S, Nuzzo G, Doglietto GB, Ambesi-Impiombato F, Cosimelli M.

Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):664-74.

PMID:
12062610
12.

Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94).

Sauer R, Fietkau R, Wittekind C, Martus P, Rödel C, Hohenberger W, Jatzko G, Sabitzer H, Karstens JH, Becker H, Hess C, Raab R.

Strahlenther Onkol. 2001 Apr;177(4):173-81.

PMID:
11370551
13.

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM).

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. Epub 2006 Jan 18.

PMID:
16414206
14.

High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.

Wolff HA, Gaedcke J, Jung K, Hermann RM, Rothe H, Schirmer M, Liersch T, Herrmann MK, Hennies S, Rave-Fränk M, Hess CF, Christiansen H.

Strahlenther Onkol. 2010 Jan;186(1):30-5. doi: 10.1007/s00066-009-2037-1. Epub 2009 Dec 28.

PMID:
20082185
15.

Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.

Lee SH, Lee KC, Choi JH, Oh JH, Baek JH, Park SH, Shin DB.

Jpn J Clin Oncol. 2008 Feb;38(2):112-21. doi: 10.1093/jjco/hym164. Epub 2008 Feb 8.

PMID:
18263881
16.

Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.

Dipetrillo T, Pricolo V, Lagares-Garcia J, Vrees M, Klipfel A, Cataldo T, Sikov W, McNulty B, Shipley J, Anderson E, Khurshid H, Oconnor B, Oldenburg NB, Radie-Keane K, Husain S, Safran H.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):124-9. doi: 10.1016/j.ijrobp.2010.08.005. Epub 2010 Oct 13.

PMID:
20947267
17.

Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.

Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H, Jakob C.

J Clin Oncol. 2006 Sep 1;24(25):4062-8.

PMID:
16943523
18.

Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies.

Gambacorta MA, Valentini V, Coco C, Morganti AG, Smaniotto D, Miccichè F, Mantini G, Barbaro B, Garcia-Vargas JE, Magistrelli P, Picciocchi A, Cellini N.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):139-48.

PMID:
15337549
19.

Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer.

Ceelen W, Boterberg T, Pattyn P, van Eijkeren M, Gillardin JM, Demetter P, Smeets P, Van Damme N, Monsaert E, Peeters M.

Ann Surg Oncol. 2007 Feb;14(2):424-31. Epub 2006 Nov 10.

PMID:
17096057
20.

A phase II study of oral UFT and leucovorin concurrently with pelvic irradiation as neoadjuvant chemoradiation for rectal cancer.

Kundel Y, Brenner B, Symon Z, Oberman B, Sadezki S, Koller M, Catane R, Pfeffer R.

Anticancer Res. 2007 Jul-Aug;27(4C):2877-80.

Supplemental Content

Support Center